HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD.

Heilongjiang ZBD Pharmaceutical Co., Ltd.

603567

CNE100002219

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
12.6 ^CNY	+0.56%		-1.41%	+3.62%

05-07	China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable	MT
04-29	Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.

October 10, 2022

From July 1, 2022 to September 30, 2022, the company has repurchased 1,716,300 shares, representing 0.18% for CNY 19.79 million. With this, the company has completed the repurchase of 1,716,300 shares, representing 0.18% for CNY 19.79 million under the buyback announced on June 10, 2022.

Latest news about Heilongjiang ZBD Pharmaceutical Co., Ltd.

China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable	05-07	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
ZBD Pharma Gets Nod for Tofacitinib Citrate Tablets	02-21	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/10/23	CI
HeiLongJiang ZBD Pharma Registers Osteoarthritis Drug	26/09/23	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to S&P Global BMI Index	18/09/23	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.(XSSC:603567) added to FTSE All-World Index	18/09/23	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23/08/23	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	10/05/23	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 10, 2022 has closed with 2,560,300 shares, representing 0.27% for CNY 30 million.	09/05/23	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	28/04/23	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	28/04/23	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	04/04/23	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	03/01/23	CI
Heilongjiang ZBD Pharmaceutical to Tie Up With Kangyue Technology on Medicine Supplies	06/12/22	MT
Heilongjiang ZBD Gets Approval for Traditional Medicine Product	04/11/22	MT
Heilongjiang ZBD’s Anti-Pulmonary Fibrosis Drug Gets U.S. Patent	02/11/22	MT
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	10/10/22	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/08/22	CI
Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.	02/08/22	CI
Huzhou Saihan Equity Investment Partnership Enterprise (Limited Partnership) completed the acquisition of 5% stake in Heilongjiang ZBD Pharmaceutical Co., Ltd. from Hulin Longpeng Investment Center.	09/06/22	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	09/06/22	CI
Heilongjiang ZBD Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	08/06/22	CI

Chart Heilongjiang ZBD Pharmaceutical Co., Ltd.

Duration

Period

Chart Heilongjiang ZBD Pharmaceutical Co., Ltd.

More charts

Company Profile

HeiLongJiang ZBD Pharmaceutical Co., Ltd. is a China-based pharmaceutical company engaged in the research and development, manufacture and sales of Chinese patent medicine. The Company's products include freeze-dried powder injections, powder injections, large volume injections, small volume injections, mixture, tablets, capsule, granules, syrup, oral solution, decoction agent and active pharmaceutical ingredient, which are used for the areas of cardiovascular, anti-viral flu, fracture and osteoporosis, immune enhancement and liver protection. The Company distributes its products under the brand named Zhenbaodao.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HEILONGJIANG ZBD PHARMACEUTICAL CO., LTD.	+3.62%	1.63B
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals

Heilongjiang ZBD Pharmaceutical Co., Ltd.

Equities

603567

CNE100002219

Pharmaceuticals

Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.

Latest news about Heilongjiang ZBD Pharmaceutical Co., Ltd.

Chart Heilongjiang ZBD Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals